- Home
- THRY vs ERAS Comparison
THRY vs ERAS Comparison
Compare THRY & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THRY
- ERAS
- Stock Information
- Founded
- THRY 2012
- ERAS 2018
- Country
- THRY United States
- ERAS United States
- Employees
- THRY N/A
- ERAS N/A
- Industry
- THRY Industrial Machinery/Components
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- THRY Industrials
- ERAS Health Care
- Exchange
- THRY Nasdaq
- ERAS Nasdaq
- Market Cap
- THRY 547.4M
- ERAS 439.7M
- IPO Year
- THRY 2020
- ERAS 2021
- Fundamental
- Price
- THRY $12.00
- ERAS $2.44
- Analyst Decision
- THRY Strong Buy
- ERAS Buy
- Analyst Count
- THRY 4
- ERAS 6
- Target Price
- THRY $20.50
- ERAS $3.67
- AVG Volume (30 Days)
- THRY 391.7K
- ERAS 2.1M
- Earning Date
- THRY 10-30-2025
- ERAS 11-07-2025
- Dividend Yield
- THRY N/A
- ERAS N/A
- EPS Growth
- THRY N/A
- ERAS N/A
- EPS
- THRY N/A
- ERAS N/A
- Revenue
- THRY $758,289,000.00
- ERAS N/A
- Revenue This Year
- THRY N/A
- ERAS N/A
- Revenue Next Year
- THRY N/A
- ERAS N/A
- P/E Ratio
- THRY N/A
- ERAS N/A
- Revenue Growth
- THRY N/A
- ERAS N/A
- 52 Week Low
- THRY $10.03
- ERAS $1.01
- 52 Week High
- THRY $20.92
- ERAS $3.31
- Technical
- Relative Strength Index (RSI)
- THRY 51.64
- ERAS 59.41
- Support Level
- THRY $10.96
- ERAS $2.18
- Resistance Level
- THRY $12.57
- ERAS $2.65
- Average True Range (ATR)
- THRY 0.41
- ERAS 0.15
- MACD
- THRY 0.13
- ERAS -0.03
- Stochastic Oscillator
- THRY 68.16
- ERAS 55.79
About THRY Thryv Holdings Inc.
Thryv Holdings Inc is dedicated to supporting local, independent service-based businesses and emerging franchises by providing a cloud-based software platform, and marketing solutions to entrepreneurs. Its company is built upon a rich legacy in the marketing and advertising industry. The group are provider of SaaS all-in-one small business management software in addition to providing print and digital marketing solutions to SMBs. Its solutions enable SMB clients to attract and generate new business leads, manage their customer relationships efficiently with artificial intelligence (AI) tools and automation, and run their day-to-day operations to save time, compete and win in today's SMB environment. The group has two business segments; Thryv SaaS and Thryv Marketing Services.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.